Role of bevacizumab for the treatment of non-small-cell lung cancer

Suresh Ramalingam, Chandra Belani

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Advanced-stage non-small-cell lung cancer (NSCLC) is a lethal disease that is treated with combination chemotherapy. Although modest survival benefit has been documented with various platinum-based, two-drug combination chemotherapy regimens, an efficacy plateau has been reached. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, is the first molecularly targeted agent that has demonstrated survival advantage when combined with chemotherapy for the treatment of advanced nonsquamous NSCLC. Improvements in all efficacy parameters, including response rate, progression-free survival and overall survival, were noted for advanced nonsquamous NSCLC patients when bevocizumab was added to the combination of carboplatin-paclitaxel compared with the same chemotherapy regimen alone. This has opened the door for expanding the role of bevacizumab in earlier stages of the disease with chemotherapy or radiotherapy. The anti-angiogenesis agents, including the monoclonal antibody and vascular endothelial growth factor tyrosine kinase inhibitors, will be among the most important drugs of the present decade. This article discusses the recent data with bevacizumab in NSCLC and its potential application at various stages of NSCLC.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalFuture Oncology
Volume3
Issue number2
DOIs
StatePublished - Apr 1 2007

Fingerprint

Non-Small Cell Lung Carcinoma
Combination Drug Therapy
Drug Therapy
Vascular Endothelial Growth Factor A
Survival
Monoclonal Antibodies
Therapeutics
Carboplatin
Drug Combinations
Paclitaxel
Platinum
Protein-Tyrosine Kinases
Disease-Free Survival
Radiotherapy
Bevacizumab
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{9cdaa32542a24e199e46b07a7240965b,
title = "Role of bevacizumab for the treatment of non-small-cell lung cancer",
abstract = "Advanced-stage non-small-cell lung cancer (NSCLC) is a lethal disease that is treated with combination chemotherapy. Although modest survival benefit has been documented with various platinum-based, two-drug combination chemotherapy regimens, an efficacy plateau has been reached. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, is the first molecularly targeted agent that has demonstrated survival advantage when combined with chemotherapy for the treatment of advanced nonsquamous NSCLC. Improvements in all efficacy parameters, including response rate, progression-free survival and overall survival, were noted for advanced nonsquamous NSCLC patients when bevocizumab was added to the combination of carboplatin-paclitaxel compared with the same chemotherapy regimen alone. This has opened the door for expanding the role of bevacizumab in earlier stages of the disease with chemotherapy or radiotherapy. The anti-angiogenesis agents, including the monoclonal antibody and vascular endothelial growth factor tyrosine kinase inhibitors, will be among the most important drugs of the present decade. This article discusses the recent data with bevacizumab in NSCLC and its potential application at various stages of NSCLC.",
author = "Suresh Ramalingam and Chandra Belani",
year = "2007",
month = "4",
day = "1",
doi = "10.2217/14796694.3.2.131",
language = "English (US)",
volume = "3",
pages = "131--139",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

Role of bevacizumab for the treatment of non-small-cell lung cancer. / Ramalingam, Suresh; Belani, Chandra.

In: Future Oncology, Vol. 3, No. 2, 01.04.2007, p. 131-139.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of bevacizumab for the treatment of non-small-cell lung cancer

AU - Ramalingam, Suresh

AU - Belani, Chandra

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Advanced-stage non-small-cell lung cancer (NSCLC) is a lethal disease that is treated with combination chemotherapy. Although modest survival benefit has been documented with various platinum-based, two-drug combination chemotherapy regimens, an efficacy plateau has been reached. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, is the first molecularly targeted agent that has demonstrated survival advantage when combined with chemotherapy for the treatment of advanced nonsquamous NSCLC. Improvements in all efficacy parameters, including response rate, progression-free survival and overall survival, were noted for advanced nonsquamous NSCLC patients when bevocizumab was added to the combination of carboplatin-paclitaxel compared with the same chemotherapy regimen alone. This has opened the door for expanding the role of bevacizumab in earlier stages of the disease with chemotherapy or radiotherapy. The anti-angiogenesis agents, including the monoclonal antibody and vascular endothelial growth factor tyrosine kinase inhibitors, will be among the most important drugs of the present decade. This article discusses the recent data with bevacizumab in NSCLC and its potential application at various stages of NSCLC.

AB - Advanced-stage non-small-cell lung cancer (NSCLC) is a lethal disease that is treated with combination chemotherapy. Although modest survival benefit has been documented with various platinum-based, two-drug combination chemotherapy regimens, an efficacy plateau has been reached. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, is the first molecularly targeted agent that has demonstrated survival advantage when combined with chemotherapy for the treatment of advanced nonsquamous NSCLC. Improvements in all efficacy parameters, including response rate, progression-free survival and overall survival, were noted for advanced nonsquamous NSCLC patients when bevocizumab was added to the combination of carboplatin-paclitaxel compared with the same chemotherapy regimen alone. This has opened the door for expanding the role of bevacizumab in earlier stages of the disease with chemotherapy or radiotherapy. The anti-angiogenesis agents, including the monoclonal antibody and vascular endothelial growth factor tyrosine kinase inhibitors, will be among the most important drugs of the present decade. This article discusses the recent data with bevacizumab in NSCLC and its potential application at various stages of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=34247175751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247175751&partnerID=8YFLogxK

U2 - 10.2217/14796694.3.2.131

DO - 10.2217/14796694.3.2.131

M3 - Article

VL - 3

SP - 131

EP - 139

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -